Abstract: A wire bonding apparatus connecting a lead of a mounted member with an electrode of a semiconductor die through a wire comprises a capillary through which the wire is inserted, a shape acquisition part which acquires the shape of the lead to which the wire is connected, a calculating part which calculates an extending direction of a wire tail extending from the end of the capillary based on the shape of a lead to which the wire is connected next, and a cutting part which moves the capillary in the extending direction and cuts the wire to form the wire tail after the lead is connected with the electrode through the wire. Thus, in the wire bonding using wedge bonding, joining part tails (183a, 283a, 383a) formed in continuation to a first bonding point can be prevented from coming into contact with each other.

Abstract: The present invention provides a novel pyrazolopyrimidine compound of the formula [I]: wherein R? is (A) a substituted aryl group, (B) an optionally substituted nitrogen-containing aliphatic heteromonocyclic group, (C) a substituted cyclo-lower alkyl group, (D) an optionally substituted amino group, or (E) a substituted heteroaryl group, R2 is (a) an optionally substituted heteroaryl group or (b) an optionally substituted aryl group, Y is a single bond, a lower alkylene group or a lower alkenylene group, Z is a group of the formula: —CO—, —CH2-, —SO2- or a group of the formula [II]: Q is a lower alkylene group, and q is an integer of 0 or 1 or a pharmaceutically acceptable sait thereof, which has a small conductance potassium channel (SK channel) blocking activity and is useful as a medicament and a process for preparing the same

Abstract: The present invention provides a novel pyrazolopyrimidine compound of the formula [I]: wherein R? is (A) a substituted aryl group, (B) an optionally substituted nitrogen-containing aliphatic heteromonocyclic group, (C) a substituted cyclo-lower alkyl group, (D) an optionally substituted amino group, or (E) a substituted heteroaryl group, R2 is (a) an optionally substituted heteroaryl group or (b) an optionally substituted aryl group, Y is a single bond, a lower alkylene group or a lower alkenylene group, Z is a group of the formula: —CO—, —CH2-, S02- or a group of the formula [II]: Q is a lower alkylene group, and q is an integer of 0 or 1 or a pharmaceutically acceptable sait thereof, which has a small conductance potassium channel (SK channel) blocking activity and is useful as a medicament and a process for preparing the same.

Abstract: An imidazopyridine derivative of the formula ?I!: ##STR1## wherein R.sup.1 is a lower alkyl group, R.sup.2 is a lower alkanoyl group, and R.sup.3 and R.sup.4 are each lower alkyl groups, or both combine at the end thereof to form an alkylene group having 3 to 6 carbon atoms, and a pharmaceutically acceptable salt thereof, said imidazopyridine derivatives have an excellent angiotensin II antagonistic activity and are useful for the prophylaxis or treatment of hypertension.

Abstract: A method of producing an aminobutene derivative of formula (I) by allowing a butenol derivative of formula (II) to react with an amide derivative of formula (III) is disclosed. The aminobutene derivative of formula (I) can be deprotected to produce an aminobutene derivative of formula (I-1) or an aminobutene derivative of formula (I-2): ##STR1## The aminobutene derivative of formula (I-A) can also be deprotected to produce the aminobutene derivative of formula (I-B). Any or all of the above aminobutene derivatives are useful as intermediates for producing anti-ulcer drugs, and anti-ulcer drugs having an inhibitory effect on gastric acid secretion based on the antagonism against histamine H.sub.2 receptor.

Abstract: An imidazopyridine derivative of formula I! is disclosed ##STR1## wherein R.sup.1 is lower alkyl, R.sup.2 is a group of the formula ##STR2## Z is oxygen, R.sup.0 is a pyridyl, furyl or thienyl group, R.sup.3 is carboxyl or lower alkoxycarbonyl, Ring A is tetrazoyl-substituted phenyl and pharmaceutically acceptable salts thereof, for use in the prophylaxis and treatment of hypertension.

Abstract: An imidazopyridine derivative is disclosed of the formula [I]: ##STR1## wherein R.sup.1 is lower alkyl, R.sup.2 is hydrogen, lower alkylsulfonyl or a group of the formula ##STR2## where Z is oxygen or two hydrogen atoms, R.sup.0 is lower alkyl, lower alkoxy, phenyl, hydrogen, di(lower alkyl) amino or lower alkenyl, R.sup.3 is carboxyl or lower alkoxycarbonyl and Ring A is substituted phenyl, and pharmaceutically acceptable salts thereof that are useful in prophylaxis and treatment of hypertension.

Abstract: An imidazopyridine derivative is disclosed of the formula [I]: ##STR1## wherein R.sup.1 is lower alkyl, R.sup.2 is a group of the formula ##STR2## where Z is oxygen atom, R.sup.0 is lower alkyl, R.sup.3 is carboxyl or lower alkoxycarbonyl and Ring A is tetrazolyl-substituted or unsubstituted phenyl, and pharmaceutically acceptable salt thereof, that are useful in prophylaxis and treatment of hypertension.

Abstract: A naphthoic acid derivative represented by the following general formula or a salt thereof: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are each independently a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group, a lower alkoxy group, a lower alkanoyloxy group, a hydroxy-lower alkyl group, a lower alkoxy-lower alkyl group, a lower alkanoyloxy-lower alkyl group or an aralkyloxy group;R.sub.4 is a hydrogen atom or a lower alkyl group;R.sub.5 is a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaromatic group;X is a group ##STR2## a cycloalkylene group, a bivalent nitrogen-containing heterocyclic group, or a group ##STR3## --R.sub.8 --NH-- or --NH--R.sub.8, where R.sub.6 and R.sub.7 are each a hydrogen atom or a lower alkyl group and R.sub.8 is a cycloalkylene group, or R.sub.6 and R.sub.7, together with R.sub.4, may form an alkylene group of 1-3 carbon atoms;Y is --S(O).sub.p --, --(CH.sub.2).sub.

Abstract: 1,4-Dihydropyridine derivatives of formula: ##STR1## wherein Ar.sup.1 represents an aromatic hydrocarbon group or an aromatic heteromonocyclic or heterobicyclic group containing therein 1 to 3 atoms selected from the group consisting of oxygen, sulfur and nitrogen; R.sup.1 represents a hydrocarbon group which may have one or more substituents; A represents (i) a straight chain or branched chain unsaturated hydrocarbon group, (ii) a cyclic unsaturated hydrocarbon group, or (iii) a group selected from the group consisting of --R--O--N.dbd.CH--, --R--N.dbd.N--, --R--CH.dbd.N-- and --R--N.dbd.CH--, in which R is an alkylene group having 1 to 6 carbon atoms; B represents an alkylene or alkenylene group having 1 to 3 carbon atoms, which may have a substituent; Ar.sup.2 represents an aromatic hydrocarbon group or a heterocyclic group; Ar.sup.

Abstract: 1,4-dihydropyridine derivatives of formula (I): ##STR1## wherein Ar.sup.1 and Ar.sup.2 each represent an unsubstituted or substituted aromatic hydrocarbon or aromatic heterocyclic group; and R.sup.1 represents --CO.sub.2 R.sup.2, --SO.sub.2 R.sup.3, --COR.sup.4, --CON(R.sup.5).sub.2, --CH--or --NO.sub.2 in which R.sup.2 is hydrogen, a straight chain, branched chain or cyclic saturated hydrocarbon group, which may have a substituent or a straight chain, branched chain or cyclic unsaturated hydrocarbon group having 2 to 10 carbon atoms, which may have a substituent, R.sup.3 is an alkyl group having 1 to 4 carbon atoms, R.sup.4 is an alkyl group having 1 to 4 carbon atoms or a phenyl group; and R.sup.5 is an alkyl group having 1 to 4 carbon atoms.

Abstract: A program replacing method is provided for an uninterruptible online computer system. The computer system includes an auxiliary storage unit for storing a program currently running in the computer system and another program to replace the current running program and a replacement request managing table for storing replacement requests and program IDs of such replacing programs. These programs include checkpoints pre-programmed at selected locations therein. At an optional checkpoint, the replacement request managing table is retrieved for checking whether or not the replacement is requested. If a replacement is requested, the new program is started according to the program ID and the current program is terminated.

Abstract: An inidazoindolizine derivative of the formula [I]: ##STR1## wherein R.sup.1 is lower alkyl, R.sup.2 is hydrogen, cyano, lower alkyl, lower alkanoyl, lower alkoxycarbonyl, phenyl-lower alkoxycarbonyl, lower alkylsulfonyl, substituted or unsubstituted phenyl, arylcarbonyl, or 5- or 6-membered nitrogen-containing heteromonocyclic group-substituted carbonyl, Ring A is substituted or unsubstituted phenyl, and m is 0 or 1, or a pharmaceutically acceptable salt thereof, and process for preparation thereof, said imidazoindolizine derivatives and pharmaceutically acceptable salts thereof show excellent angiotensin II inhibitory activities and are useful in the prophylaxis or treatment of hypertension.

Abstract: A phenoxypropyl derivative represented by the following formula ##STR1## wherein A represents a formyl group, a protected formyl group, a hydroxymethyl group, a protected hydroxymethyl group, or a halomethyl group, and Z represents a halogen atom, an amino group, a phthalimide group or a group of the formula ##STR2## in which n is 0, 1 or 2.

Abstract: The compounds of the formulas (VI) and (VII) are useful intermediates in producing pyridyloxy derivatives of the formula (I), such as, for instance, N-{4-[4-(piperidinomethyl)pyridyl-2-oxy]-2-butenyl}-2-(furfurylt hio)acetamide, which are useful as anti-peptic ulcer agents. The compounds of formula (VI) have the formula ##STR1## wherein A represents a formyl group, a protected formyl group, a hydroxymethyl group or a protected hydroxymethyl group. The compounds of formula (VIII) have the formula ##STR2## wherein G represents a formyl group, a protected formyl group, a hydroxymethyl group, a hydroxymethyl group in which the hydroxyl group is protected, or a halogenomethyl group, Y represents --CH.sub.2 --CH.sub.2 -- or --CH.dbd.CH--, and n is 0, 1 or 2.

Abstract: There are disclosed are glycine derivative of the formula: ##STR1## (wherein R.sup.1 represents a substituted or unsubstituted phenyl group, R.sup.2 represents a carboxyl group which may be protected, Q represents a lower alkylene group and m represents 0 or 1) or a pharmacologically acceptable salt thereof and a process for preparing the same.

Abstract: A compound represented by the following formula or a salt thereof ##STR1## wherein each of R.sub.1 and R.sub.2 represents a lower alkyl group, or R.sub.1 and R.sub.2, together with the nitrogen atom to which they are bonded, may form a substituted or unsubstituted, saturated or partially unsaturated 4- to 8-membered heterocyclic group which may contain a hetero atom selected from N, O and S, Y represents a group of the formula --CH.sub.2 --CH.sub.2 -- or --CH.dbd.CH--, and n is 0, 1 or 2. This compound is useful as anti-peptic ulcer agent.

Abstract: Alkylamide derivatives having the formula, These compounds have a strong antiulcer action depend on histamine H.sub.2 -receptor antagonistic action and a cytoprotective action upon gastric mucous membrance.